AVNS:NYE-Avanos Medical Inc (USD)

COMMON STOCK | Medical Devices | NYE

Last Closing Price

USD 29.09

Change

+0.78 (+2.76)%

Market Cap

USD 1.36B

Volume

0.33M

Avg Analyst Target

USD 33.75 (+16.02%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


AVNS Stock Forecast & Price:
Based on the Avanos Medical Inc stock forecasts from 3 analysts, the average analyst target price for Avanos Medical Inc is USD 33.75 over the next 12 months. Avanos Medical Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Avanos Medical Inc is Bearish, which is based on 3 positive signals and 9 negative signals. At the last closing, Avanos Medical Inc’s stock price was USD 29.09. Avanos Medical Inc’s stock price has changed by +0.97% over the past week, +8.54% over the past month and -14.42% over the last year.

About Avanos Medical Inc (AVNS:NYE)

Avanos Medical, Inc., a medical technology company, focuses on delivering medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such a ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-12 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ABT Abbott Laboratories

+0.99 (+0.90%)

USD193.49B 23.07 14.38
MDT Medtronic PLC

+0.78 (+0.83%)

USD125.77B 25.25 15.64
SYK Stryker Corporation

+5.11 (+2.34%)

USD81.32B 39.59 25.86
EW Edwards Lifesciences Corp

+0.88 (+0.85%)

USD64.42B 43.85 33.17
BSX Boston Scientific Corp

+0.57 (+1.36%)

USD59.78B 70.78 25.18
ZBH Zimmer Biomet Holdings Inc

+2.22 (+1.93%)

USD24.13B 83.33 19.03
STE STERIS plc

+3.69 (+1.76%)

USD21.04B 55.03 20.29
PHG Koninklijke Philips NV ADR

+0.05 (+0.25%)

USD17.93B 44.81 14.17
BIO Bio-Rad Laboratories Inc

-0.38 (-0.07%)

USD16.16B 3.61 -6.32
BIO-B Bio-Rad Laboratories Inc

N/A

USD15.32B 3.59 -6.32

ETFs Containing AVNS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Devices)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -16.09% 57% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.09% 53% F 28% F
Trailing 12 Months  
Capital Gain -15.04% 72% C- 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.04% 69% D+ 31% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -7.19% 14% F 10% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -7.19% 14% F 8% F
Risk Return Profile  
Volatility (Standard Deviation) 29.63% 55% F 37% F
Risk Adjusted Return -24.28% 14% F 14% F
Market Capitalization 1.36B 33% F 55% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Devices)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 72.10 32% F 8% F
Price/Book Ratio 1.06 90% A- 68% D+
Price / Cash Flow Ratio 15.63 53% F 27% F
EV/EBITDA 21.90 23% F 12% F
Management Effectiveness  
Return on Equity 1.48% 57% F 27% F
Return on Invested Capital 0.59% 45% F 28% F
Return on Assets 0.97% 48% F 29% F
Debt to Equity Ratio 10.29% 74% C 87% B+
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 4.57 43% F 26% F
Short Percent 3.36% 45% F 54% F
Beta 0.84 77% C+ 67% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on assets

The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector